Traffic Quality Sample Clauses

Traffic Quality. For each Query and each click on a Paid Result, Publisher will provide: (a) the user agent; (b) the full, unencrypted Internet Protocol address of the user; (c) the referring URL (HTTP Referrer); (d) any anonymous user identification ascribed by Publisher, unique cookie or URL tag; and (e) any other data that Overture requests in writing that is used in connection with Overture’s ad serving and quality systems. Publisher will provide this information at the time a Query is sent to Overture and when a user clicks on a Paid Result. For clarity, Overture will not request and Publisher will not share any personally identifiable information with Overture. Additionally, Publisher will utilize the URLs and other source feed indicators designated from time to time by Overture. The parties will cooperate in a commercially reasonable manner to minimize automated, fraudulent or lower quality traffic. Overture will have no obligation to make payments in instances when Publisher has failed to utilize designated source feed indicators correctly. Overture shall determine the validity and quality of all traffic in its reasonable discretion.
Sample 1Sample 2
AutoNDA by SimpleDocs
Traffic Quality. For each Query and each click on a Paid Result, Publisher will provide: (a) the User agent; (b) the full unencrypted Internet Protocol address of the User (unless such provision is in violation of applicable law, in which case the parties agree to work in good faith and use commercially reasonable efforts to provide Yahoo! with such information in a form and manner that complies with applicable law); and (c) the serve URL (in such form as mutually agreed upon by the parties). To the extent Yahoo! requests in writing that Publisher provide any additional data for use by Yahoo! in connection with ad serving and quality systems, Publisher will [*] provide such additional data; provided that, the provision of such data to Yahoo! does not violate any applicable law, rule or regulation. Publisher will provide this information along with the Internet Protocol address of its own or the Affiliate’s server, as the case may be, at the time a Query is sent to Yahoo! and when a user clicks on a Paid Result. For clarity, Publisher will not share any personally identifiable information with Yahoo! as part of sending Queries to Yahoo! hereunder (incidental transmission of personally identifiable information by a User is excluded). Additionally, Publisher will utilize the URLs and other source feed indicators designated from time to time by Yahoo!. The parties will * Information redacted pursuant to a confidential treatment request by InfoSpace, Inc. under 5 U.S.C. §552(b)(4) and 17 C.F.R. §§ 200.80(b)(4) and 240.24b-2, and submitted separately with the Securities and Exchange Commission. EXECUTION COPY YAHOO! PUBLISHER NETWORK CONTRACT #1- 23975446 cooperate [*] to minimize automated or fraudulent traffic. Yahoo! will have no obligation to make payments (i) in instances when Publisher has failed to utilize designated source feed indicators correctly and Yahoo! cannot, using its routine business practices, accurately identify the source of associated Gross Revenue, or (ii) for any amounts generated from automated or fraudulent traffic. Yahoo! shall determine the validity of all traffic using commercially reasonable standards.
Sample 1
Traffic Quality. Intelius shall (* * *) use its best efforts (* * *)
Sample 1
Traffic Quality. Pursuant to the Oath Agreement, all traffic must adhere to traffic quality targets of 7 for desktop and 5 for mobile (the “Oath Traffic Quality Requirements”), unless BRIGHTCAST modifies those targets for any reason (email sufficing). Company will use commercially reasonable efforts to comply with the Oath Traffic Quality Requirements. If BRIGHTCAST reasonably believes the Oath Traffic Quality Requirements are not being met, Company will pause any campaign within three hours upon written request from BRIGHTCAST during standard business hours. If Company is unable to pause a campaign within three hours of receipt of a written request from BRIGHTCAST during standard business hours, BRIGHTCAST, at its sole discretion, may disable the lander page(s).
Sample 1
Traffic Quality. The parties will cooperate in a commercially reasonable manner to minimize automated, fraudulent or lower quality traffic. Microsoft will determine the validity and quality of all traffic in its reasonable discretion.
Sample 1
Traffic Quality. For each Query and each click on a Paid Result, Publisher will provide: [*]. To the extent Overture requests in writing that Publisher provide any additional data for use by Overture in connection with Overture’s ad serving and quality systems, Publisher will [*] provide such additional data, provided the provision of such data to Overture does not [*]. Publisher will provide this information along with the Internet Protocol address of its own or the Affiliate’s server, as the case may be, at the time a Query is sent to Overture. For clarity, Publisher will not share any [*] with Overture as part of sending Queries to Overture hereunder (incidental transmission of [*] is excluded). Additionally, Publisher will utilize the URLs and other source feed indicators designated from time to time by Overture. The parties will [*] automated or fraudulent traffic. Overture will have no obligation to make payments [*].
Sample 1
Traffic Quality. The Sites shall not i) contain content that promotes any illegal or dangerous activity; ii) contain content with foul, vulgar, obscene or defamatory language or images; iii) run Ad Network ads next to or before pornographic content; iv) create “forced visit” traffic; v) create invisible or nested (Frames loading pages or ads; vi) intentionally falsify clicks: vii) modify or obscure display of ads; viii) fraudulently generate requests or clicks; or ix) use any means of artificially generating ad impressions or clicks, including third-party services such as paid-to-click, paid-to-surf, auto-surf, and click-exchange programs.
Sample 1
AutoNDA by SimpleDocs

Related to Traffic Quality

  • Money Market Fund Compliance Testing and Reporting Services Subject to the authorization and direction of the Trust and, in each case where appropriate, the review and comment by the Trust’s independent accountants and legal counsel, and in accordance with procedures that may be established from time to time between the Trust and the Administrator, the Administrator will:

  • Monitoring and Reporting Monitoring shareholder transactions and identifying and reporting suspicious activities that are required to be so identified and reported, including suspicious activity reports or Form 8300 reports, and provide other reports of shareholder activity to the Securities and Exchange Commission, the U.S. Treasury Department, the Internal Revenue Service, and other appropriate authorities, in each case consistent with the Unified AML Program.

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials conducted by the Company, and to the knowledge of the Company, the preclinical tests and clinical trials conducted on behalf of or sponsored by the Company, that are described in, or the results of which are referred to in, the Registration Statement, the Time of Sale Prospectus or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures and all applicable laws and regulations, including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58, and 312; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the Time of Sale Prospectuses or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such Permits as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”) for the operation of the Company’s business as currently conducted, except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement, the Time of Sale Prospectus or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules and regulations of the Regulatory Agencies except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

  • Environmental, Health and Safety The Policy Board shall review, approve and monitor environmental and workplace health and safety guidelines, the goal of which is to achieve compliance with current national, state and local laws and regulations regarding environmental and workplace health and safety.

  • Quality Assurance Licensee agrees that all use of the Licensed Subject Matter shall be only upon the Products manufactured by or for Licensee in accordance with quality standards approved by Licensor prior to the commencement of manufacturing of the Products. Licensee shall submit for Licensor's sole and absolute approval the type of cereal, the name of cereal, the packaging design, advertising material, and all other materials to be used in connection with the Products subject to the sole and absolute approval of Licensor which shall not be unreasonably delayed or withheld.

  • Health and Safety All employees and workers have a duty in law to act responsibly and to take reasonable care for the health and safety at work of both themselves and their colleagues. This duty can be carried out by:

  • SAFETY AND HEALTH All sources supplying coal purchased under this contract shall be in full compliance with the Federal Mine Safety and Health Act of 1977 and regulations issued thereunder. Failure to comply shall constitute a breach of contract, permitting TVA to exercise its remedies under this contract or as provided by law.

  • Adverse Event Reporting Sage shall adhere, and shall require that its Affiliates, Sublicensees, co-marketers and distributors adhere, to all requirements of applicable law and regulations that relate to the reporting and investigation of any adverse event, including without limitation an unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease, whether or not considered Captisol. Probe Study Product-related or Licensed Product-related, which occurs or worsens following administration of Captisol, Probe Study Product or Licensed Product. Sage shall provide CyDex with copies of ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 all reports of any such adverse event which is serious (any such adverse event involving Captisol, the Probe Study Product or the Licensed Product that results in death, is life-threatening, requires or prolongs inpatient hospitalization, results in disability, congenital anomaly or is medically important (i.e., may require other medical or surgical intervention to prevent other serious criteria from occurring)) which Sage has reason to believe are associated with Captisol within 10 business days following (i) Sage’s submission of any such report to any regulatory agency, or (ii) receipt from Sage’s Sublicensee, co-marketer or distributor of any such report to any regulatory agency. Sage shall also advise CyDex regarding any proposed labeling or registration dossier changes affecting Captisol. Reports from Sage shall be delivered to the attention of Chief Scientific Officer, CyDex, with a copy to General Counsel, Ligand, at the address set forth in Section 14.7. The parties shall mutually cooperate with regard to investigation of any such serious adverse event, whether experienced by Sage, CyDex or any other Affiliate, Sublicensee, co-marketer or distributor of CyDex or Sage.

  • Research Analyst Independence The Company acknowledges that the Underwriters’ research analysts and research departments are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriters’ research analysts may hold views and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of their respective investment banking divisions. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against the Underwriters with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriters’ investment banking divisions. The Company acknowledges that each of the Underwriters is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the companies that may be the subject of the transactions contemplated by this Agreement.

  • Environmental, Health and Safety Matters (a) The Company has complied and is in compliance with all Environmental, Health, and Safety Requirements.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!